{"date":"2026-06-13","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6696-2026-06-13-1113-174ab0q","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-06-13","time":"11:13:03","subject":"代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥LBS-008向美國食品藥物管理局(FDA)完成新藥查驗登記申請滾動式送件(Rolling Submission of NDA)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-06-13 11:13，「代重要子公司Belite Bio, Inc公告用於治療斯特格病變新藥LBS-008向美國食品藥物管理局(FDA)完成新藥」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}